EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of HBeAG-negative chronic hepatitis B with sequential lamivudine and interferon-alfa courses of 12-month duration and a 6-month overlap



Treatment of HBeAG-negative chronic hepatitis B with sequential lamivudine and interferon-alfa courses of 12-month duration and a 6-month overlap



Journal of Hepatology 38(Supplement 2): 152-153, April




(PDF 0-2 workdays service: $29.90)

Accession: 035980438

Download citation: RISBibTeXText



Related references

Treatment of HBeAg-negative chronic hepatitis B with sequential lamivudine and interferon of 12-month duration and a 6-month overlap Preliminary results. Hepatology 36(4 Part 2): 641A, October, 2002

Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. Journal of Gastroenterology and Hepatology 22(10): 1582-1588, 2007

Long-term outcome of patients with HBeAg-negative chronic hepatitis B treated with a 24-month course of interferon alfa. Gastroenterology 120(5 Supplement 1): A 572, April, 2001

Efficacy of the treatment of HBeAg-negative chronic hepatitis B patients with lamivudine Results of 12 month therapy. Hepatology 36(4 Part 2): 637A, October, 2002

Sequential combination therapy with prednisone, lamivudine and interferon alfa-2b for HBeAg-positive chronic hepatitis B. Gastroenterologia Y Hepatologia 29(9): 534-541, 2006

A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative. Hepatology 42(1): 77-85, 2005

Three-year follow-up of pegylated interferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B. Scandinavian Journal of Gastroenterology 44(8): 1021-1022, 2010

Better efficacy of a 12-month interferon Alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: A multicenter, controlled, randomized trial. Hepatology 28(6): 1680-1686, 1998

HBsAg seroconversion after pegylated interferon alfa 2a rescue in a lamivudine-resistant patient with HBeAg-negative chronic hepatitis B and favourable IL28-B genotype. Le Infezioni in Medicina 24(2): 144-146, 2016

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatology International 2(1): 102-110, 2008

Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'├ętude et De Traitement du Virus De L'h├ępatite C (Get.Vhc). Hepatology 28(6): 1680-1686, 1998

Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. Cochrane Database of Systematic Reviews (): Cd000345-Cd000345, 2005

Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Hepatology 27(4): 1121-1127, 1998

Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. Clinical Infectious Diseases 36(12): 1516-1522, 2003

Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon Alfa-2b: Results of an international randomized controlled trial. Hepatology 27(4): 1121-1127, 1998